Equity Method and Other Equity Investments - Additional Information (Detail)	1 Months Ended	3 Months Ended			6 Months Ended		12 Months Ended
	Oct. 31, 2019 USD ($) Director shares	Dec. 31, 2021 USD ($)		Jun. 30, 2021 USD ($)	Jun. 30, 2022 USD ($)	Jun. 30, 2021 USD ($)	Dec. 31, 2021 USD ($)		Nov. 01, 2021	Mar. 31, 2021 USD ($)
Schedule Of Equity Method Investments [Line Items]
Fair value of warrants		$ 2,100,000			$ 800,000		$ 2,100,000
Equity security investment		49,148,000	[1]		27,141,000		49,148,000	[1]
LEO call option liability										$ 0
LianBio
Schedule Of Equity Method Investments [Line Items]
Equity security investment		30,800,000			10,800,000		30,800,000
LianBio | Equity Method Investee's IPO
Schedule Of Equity Method Investments [Line Items]
Ownership interest									4.70%
Gain on conversion from equity method investment to investment in equity securities		$ 68,500,000
Unrealized loss on ongoing mark-to-market adjustments of investment in equity security					$ 57,700,000		$ 37,700,000
Bridge Bio Pharma Limited Liability Company | Entities Affiliated With Perceptive Life Sciences Master Fund Ltd | LianBio
Schedule Of Equity Method Investments [Line Items]
Ownership interest	10.00%
Number of directors appoint or removal | Director	1
Ownership interest, value	$ 3,800,000
Impairments related investment				$ 0		$ 0
Warrant to purchase percentage	10.00%
Warrants to purchase common stock | shares	347,569

[1] The condensed consolidated balance sheet as of December 31, 2021 is derived from the audited consolidated financial statements as of that date.